中基長壽科學集團有限公司 （於百慕達註冊成立之有限公司） （股份代號：767） 自願公告 合作備忘錄 本公告由中基長壽科學集團有限公司（「本公司」，連同其附屬公司，「本集團」）自願 作出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Zhong Ji Longevity Science Group Limited 備忘錄 本公司董事（「董事」）會（「董事會」）欣然宣佈，於二零二五年七月二十九日，本公司 之全資附屬公司浤烽發展有限公司（「浤烽發展」）與好柿多（深圳）生物科技有限公司 （「好柿多」）訂立合作備忘錄（「備忘錄」），據此，浤烽發展與好柿多有意共同合作長 壽檢測、長壽管理等業務，為客戶提供長壽生物製品、長壽醫學檢測、健康諮詢服 務、長壽管理等大健康產業產品及服務。 擬進行之合作事項將包括浤烽發展負責提供產品服務及管理系統的支援，好柿多負 責為浤烽發展提供國內客戶資源及市場銷售管道。 – 1 – 關於好柿多之資料 好柿多是一家於二零二五年於 ...

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 4.4%, with a year-to-date increase of over 100% [1] - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index increased by 4.0%, while the CSI Innovative Drug Industry Index rose by 3.0% [1] - The CSI Biotechnology Theme Index and the CSI 300 Pharmaceutical and Health Index saw increases of 2.6% and 2.5%, respectively [1] Group 2 - The Hang Seng Innovative Drug ETF (159316) has seen continuous inflows for 10 trading days, reaching a record size of over 800 million yuan [1] - The CSI Biotechnology Theme Index, which focuses on A-share biotechnology leaders, has a rolling price-to-earnings ratio of 59.8 times and has increased by 2.6% [4] - The CSI 300 Pharmaceutical and Health Index, which covers leading companies in the pharmaceutical and health industry, has a rolling price-to-earnings ratio of 31.4 times and has increased by 2.5% [4]

Core Viewpoint - Guangxin Group has been recognized in the 2025 Fortune Global 500 list, emphasizing its commitment to high-quality development and its role as a leader in the Guangdong-Hong Kong-Macao Greater Bay Area's new industries [1] Group 1: Business Strategy and Industry Focus - Guangxin Group focuses on three main sectors: new energy and materials, biotechnology and food health, and digital services and supply chain services, aiming to enhance its core advantages in manufacturing, state-owned capital investment, and international operations [1][3] - The company has established a "4+4+2" industrial layout, promoting four pillar industries and four emerging industries, while also fostering two future industries to optimize its industrial structure [4][5] Group 2: Nickel and Aluminum Industry Development - Guangxin Group has created a billion-level multinational nickel alloy industry chain, with significant projects in Indonesia contributing nearly 50 billion yuan in revenue last year [5] - The aluminum alloy sector has seen substantial growth, with the company’s subsidiary achieving a leading market share in China and expanding its production capabilities internationally [6] Group 3: Biotechnology and Food Health - The biotechnology and food health sector is becoming a key growth area for Guangxin Group, with its subsidiary Star Lake Technology ranking among the top three global players in the bio-fermentation industry after a major asset restructuring [7] Group 4: Technological Innovation and Manufacturing Upgrade - Guangxin Group emphasizes technological innovation as a driver for modern industrial development, with a focus on talent, projects, and funding to enhance its innovation system [11][12] - The company is advancing its manufacturing capabilities through smart and green technologies, establishing smart factories and promoting industrial internet platforms [12] Group 5: Global Expansion and International Operations - Guangxin Group is actively pursuing international expansion, with overseas revenue accounting for 40% of its total, particularly in ASEAN countries [16] - The company supports Chinese enterprises in entering international markets, significantly increasing its overseas business [17] Group 6: Social Responsibility and Sustainability - Guangxin Group is committed to social responsibility and has implemented various initiatives to support local economies and promote sustainable practices, including significant investments in agriculture and green projects [19][20] - The company has set ambitious carbon reduction goals and has been recognized for its green manufacturing practices [20] Group 7: Future Outlook - Standing at a new starting point after being listed in the Fortune Global 500, Guangxin Group aims to continue its focus on industrial development and contribute to the modernization of the industrial system [21]

1. Report Industry Investment Rating No information about the report industry investment rating is provided in the content. 2. Report's Core Viewpoints - The Hang Seng Biotech Index (HSHKBIO) consists of 50 constituent stocks with notable investment scarcity, and foreign investors hold strong pricing power, influencing the AH premium. The index is affected by factors such as U.S. bond yields, credit spreads, and market liquidity [9][11]. - The index shows different correlations and trends with various factors, including a negative correlation with U.S. Treasury yields, a similar trend with Moutai Basket and Ning Portfolio, a closer alignment with A - share healthcare indices, and better performance when credit spreads widen [101][114][126]. - The trading behavior of foreign capital impacts the AH premium from aspects such as substitution, risk appetite, sentiment, and market liquidity [179][188]. 3. Summary According to the Table of Contents 3.1 Introduction - **Three Major Healthcare Sector Indices in Hong Kong Stocks**: There are three major industry indices in the Hong Kong healthcare sector: the HS Healthcare Index (68 constituents), the HS Biotechnology Index (50 constituents), and the HS Innovative Drug Index (37 constituents). The first two have high long - term correlation, and the Biotech Index can more effectively track the leading Hong Kong healthcare stocks due to its quarterly rebalancing [21][25]. - **Focus on Drugs and Medical Devices**: Hong Kong pharmaceutical stocks have scarcity as many innovative biotech companies are listed there before the STAR Market. The Biotech Index focuses on innovative drugs, medical devices, and CXO, different from A - share listed pharmaceutical enterprises [26][33]. - **The Low Proportion of AH Shares**: By April 2025, 13 AH shares in the index accounted for 17% - 20% of the index weight. Except for WuXi AppTec, the AH premium of other AH shares is generally around 1.5 - 2.0, and it may climb above 2.0 during market declines [38][42]. 3.2 Pricing Power - **Capital Structure**: Foreign and Hong Kong capital hold a dominant position (61% - 80%) in the Hang Seng Biotech Index. Since 2023, foreign capital has been reducing holdings, leading to a passive increase in the proportion of Southbound Stock Connect. By the end of March 2025, domestic and Chinese - funded institutions' investment proportion rose to 30% [51][55]. - **Proportion of Foreign Capital's Holdings**: Foreign capital holds controlling stakes in most individual stocks in the Hong Kong pharmaceutical sector, mainly from Europe and the United States. In 2024, U.S. - based foreign capital rapidly reduced its holdings, and some equity was transferred to the Qatar Investment Authority [60][64]. - **Belonging of Pricing Power**: From 2021 to 2025, foreign institutional investors had strong pricing power over pharmaceutical stocks, with more than half of the individual stocks showing a correlation coefficient exceeding 0.5 between their stock prices and the proportion of foreign holdings. Based on foreign ownership fluctuations for market timing has a long - term alpha effect [75][86]. 3.3 Sector Rotations - **The Index is Negatively Correltated with the U.S. Treasury Yield**: The HS Biotech Index has a significant negative correlation (- 0.84) with the 10 - year U.S. Treasury yield. Since 2024, its correlation with long - term Chinese bond yields has strengthened [95][101]. - **The Index Moves in Tandem with Moutai Basket and Ning Portofolio**: The Hang Seng Biotech Index, Moutai Basket, and Ning Portfolio are all dominated by foreign capital, tied to U.S. Treasury yields. They peaked simultaneously in 2021, with different maximum drawdowns [108][114]. - **The Index Tracks A - Share Healthcare Indices More Closely**: The HS Biotech Index shows stronger alignment with A - share healthcare indices and has diverged from U.S. biotech indices since 2024. After 2024, its trajectory is mainly driven by China's economic expectations [120][126]. - **The Index Paradoxically Outperforms When Credit Spreads Widen**: Credit spreads typically expand during macro - economic deterioration or industry profit headwinds. Widening spreads imply a higher probability of interest - rate cuts, boosting biotech valuations [133][139]. - **Hang Seng Sector Rotation Signals**: When the 10 - year U.S. Treasury yield declines, the elasticity of Hong Kong's major broad - based indices is Biotech > HSTECH > HSI; in the interest - rate hike cycle, HSI and HSTECH have stronger excess returns. When the 10 - year CGB yield rises, it is suitable to overweight the Biotech Index [147][158]. 3.4 AH Premium - **AH Premium Rate: Negatively Correlated with the Index**: The average AH premium of 13 AH shares from September 2022 to March 2025 has a high negative correlation (- 0.90) with the index, which may be due to the high elasticity of biopharmaceutical stocks and the significant influence of foreign capital transactions [165][166]. - **AH Premium: The Trading Behavior of Foreign Capital**: The trading behavior of foreign capital affects the AH premium from four aspects: substitution (long - term deviation in AH premium after the launch of the Mainland - Hong Kong Stock Connect), risk appetite (higher U.S. Treasury yields lead to a higher AH premium), sentiment (negative correlation between warrant PCR ratio and AH premium), and market liquidity (lower Hong Kong stock liquidity leads to a higher AH premium) [174][179][188].

Group 1 - The pharmaceutical and biotechnology industry is experiencing high growth in innovative drugs, with recent government support aimed at reducing internal competition and promoting innovation [1] - The National Medical Insurance Administration has indicated that the 11th batch of centralized procurement will optimize specific rules, moving away from solely considering the lowest bid [1] - The SW pharmaceutical index rose by 1.9% in the fourth week of July 2025, with notable performances in the medical services sector (+6.7%) and medical devices (+4.4%) [1] Group 2 - The CXO and upstream pharmaceutical sectors are seeing a recovery in their business environment, while the medical device sector is expected to benefit further from policy optimizations [1] - The current premium rate of the pharmaceutical sector relative to the entire A-share market stands at 88.0%, indicating a normal level [1] - The CS Bio-Medical Index, which the Biopharmaceutical ETF (512290) tracks, includes listed companies involved in biotechnology, pharmaceuticals, and medical devices, reflecting the overall performance of the biopharmaceutical sector [1]

Core Viewpoint - The company has successfully completed its second share repurchase plan for 2025, aimed at maintaining company value and protecting shareholder interests, with a total repurchase amount of approximately 110 million RMB [1][2][3]. Summary by Sections Repurchase Plan Details - The repurchase plan was first disclosed on April 30, 2025, with an implementation period from April 28, 2025, to July 25, 2025 [1]. - The expected repurchase amount ranges from 60 million RMB to 120 million RMB, with a maximum repurchase price set at 25.05 RMB per share [1]. - The repurchased shares are intended for maintaining company value and shareholder rights, and may also be used for employee stock ownership plans or convertible bond conversions [1]. Implementation Status - As of the announcement date, the company has repurchased a total of 5,829,475 shares, representing 3.03% of the total share capital of 192,157,999 shares [2][3]. - The repurchase was conducted at a price range of 16.50 RMB to 23.69 RMB per share, with an average price of 18.87 RMB per share, totaling approximately 110 million RMB [2][3]. Financial Impact - The funds used for the repurchase include self-owned funds and a special loan from a bank, which will not significantly impact the company's operational activities, financial status, or future development [3]. - The completion of the share repurchase will not lead to any changes in company control or affect its listing status [3]. Shareholder Transactions - During the repurchase period, there were no stock transactions by the company's directors, supervisors, senior management, controlling shareholders, or actual controllers [4]. Share Changes and Future Plans - Before the repurchase, the total number of shares was 192,157,999, and after the repurchase, the number of shares held in the repurchase account increased from 8,808,833 to 14,638,308 [4]. - The repurchased shares will be sold through centralized bidding within 12 months after the announcement of the repurchase results, and if not sold within three years, the unsold shares will be canceled [5].

Core Viewpoint - The performance of major industry ETFs in the U.S. stock market shows mixed results, with semiconductor and energy ETFs experiencing gains, while utility ETFs decline. Group 1: Semiconductor and Energy ETFs - The semiconductor ETF is priced at $290.69, with an increase of $3.20 (+1.11%) and a total market capitalization of $34.36 billion, reflecting a year-to-date increase of 20.04% [2] - The energy ETF is priced at $87.86, rising by $0.76 (+0.87%) with a trading volume of 1.88 million shares and a total market capitalization of $22.00 billion, showing a year-to-date increase of 4.20% [2] Group 2: Other Industry ETFs - The technology sector ETF is priced at $263.36, decreasing by $1.37 (-0.52%) with a market capitalization of $83.76 billion, up 13.65% year-to-date [2] - The consumer discretionary ETF is priced at $225.45, increasing by $0.58 (+0.26%) with a market capitalization of $28.32 billion, reflecting a year-to-date increase of 0.98% [2] - The financial sector ETF is priced at $53.35, declining by $0.09 (-0.17%) with a market capitalization of $593.81 billion, up 11.17% year-to-date [2] - The utility ETF is priced at $83.65, decreasing by $0.87 (-1.03%) with a market capitalization of $12.14 billion, reflecting a year-to-date increase of 12.07% [2]

Core Viewpoint - The Hong Kong stock market is experiencing a surge in new listings, particularly from new economy enterprises, Chinese concept stocks, and biotechnology companies, creating significant investment opportunities for various investors [1][3]. Group 1: Primary Market Insights - Investors focusing on the primary market can benefit from cornerstone investments or public subscriptions in popular IPOs, which may offer attractive valuations compared to future growth potential, especially during periods of market recovery and rational pricing [3]. - The return of Chinese concept stocks to the Hong Kong market often leads to improved liquidity and increased attention from local investors [3]. - The risk of new stocks breaking below their offering price remains, making it essential to conduct thorough research on company fundamentals, valuation rationality, and market subscription enthusiasm [3]. Group 2: Secondary Market Implications - The influx of quality companies, particularly in new economy, technological innovation, and biomedicine sectors, significantly enriches the investment options available to investors, facilitating the construction of portfolios aligned with future industry trends [3]. - The concentrated issuance of new stocks and large IPOs may create a short-term siphoning effect on market liquidity, potentially impacting overall market volatility [3]. - In the long term, the continuous introduction of quality companies is expected to enhance the overall competitiveness and attractiveness of the Hong Kong stock market [3]. Group 3: Investment Strategy Recommendations - Investors are advised to maintain a rational and strategic approach towards the Hong Kong listing boom, treating new stock investments as part of a broader portfolio rather than the entirety [5]. - It is crucial to focus on structural opportunities driven by the long-term growth of quality newly listed companies, rather than engaging in short-term speculative trading [5]. - Conducting in-depth research on industry prospects, core competitive advantages, and governance structures is deemed more important than merely chasing listing concepts [5]. - Utilizing diversified tools, such as ETFs covering new economy sectors, can aid in risk diversification, while professional support can help in formulating cautious new stock participation strategies [5].

Investment Rating - The report maintains a "Buy" rating for the company [2][11] Core Views - The company has entered into a licensing agreement with Pfizer for the PD-1/VEGF dual antibody, which is expected to enhance its market position and revenue potential [2][6] - The peak sales forecast for the product has been raised to RMB 6.6 billion (approximately USD 900 million) due to the collaboration with Pfizer [6] - The target price for the company's stock has been increased to HKD 33.00, reflecting a potential upside of 16% from the current price [2][6] Financial Projections - Revenue projections for 2025 have been increased by 6% to RMB 20,316 million, with further growth expected in subsequent years [5][12] - Gross profit for 2025 is projected at RMB 18,812 million, with a gross margin of 92.6% [5][12] - Net profit for 2025 is forecasted to be RMB 9,372 million, representing a 9% increase from previous estimates [5][12] Market Position - The company is transitioning from reliance on traditional blockbuster products to a strategy focused on new product iterations and international expansion, indicating a significant growth opportunity [6][7] - The stock has shown a remarkable year-to-date increase of 367.93%, highlighting strong market performance [4]

Core Viewpoint - The article highlights the successful IPO of Nanjing Weili Zhizhi Biotechnology Co., Ltd. on the Hong Kong Stock Exchange, emphasizing the long-term investment strategy and support from Huafang Capital throughout the company's development journey [1][3]. Group 1: Company Overview - Nanjing Weili Zhizhi Biotechnology, founded in 2012, focuses on discovering, developing, and commercializing new therapies for tumors, autoimmune diseases, and other major diseases [3]. - The company became the first stock in the TCE (T-cell Engager) field in China, backed by top-tier institutions including Morgan Stanley and CITIC Securities, with cornerstone subscriptions exceeding half of the total issuance [3]. Group 2: Investment Journey - Huafang Capital's initial investment in Weili Zhizhi in 2018 marked a significant turning point, as the company was still in the pre-clinical stage at that time [4]. - In 2019, Huafang Capital, along with its parent company, led a new round of investment totaling 200 million yuan to help Weili Zhizhi navigate through a critical phase of development [5]. Group 3: Market Performance - On its first day of trading on July 25, 2025, Weili Zhizhi's stock opened at 72.4 HKD per share, reaching a peak of 79.6 HKD, with a maximum increase of 127.43%, and closing at 67.1 HKD, reflecting a 91.71% rise, resulting in a market capitalization of 12.97 billion HKD [1][3]. Group 4: Huafang Capital's Strategy - Established in 2017, Huafang Capital specializes in early-stage investments in high-end manufacturing, biomedicine, and new-generation information technology, leveraging its extensive industry and capital operation experience [6]. - The firm emphasizes post-investment empowerment and has formed a strategic layout targeting leading companies in niche sectors [6].